test

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a IN CANADA UNTIL 2033

For Immediate Release February 2, 2021

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from  the Canadian Intellectual Property Office for a new patent application covering Adva-27a, the  Company’s flagship anticancer compound. This newly issued patent contains new subject matter  and extends the proprietary protection of Adva-27a in Canada until 2033. The equivalent patent  in the United States was issued in 2019 (US Patent Number 10,272,065) and similarly covers Adva-27a until 2033. The analogous patents are still pending in Europe. Sunshine Biopharma is  the sole owner of all intellectual property rights pertaining to Adva-27a, including the first Adva 27a patent (US Patent Number 8,236,935) issued in 2012. 

“We are very excited about this significant development for Adva-27a,” said Dr. Steve N. Slilaty,  CEO of Sunshine Biopharma. “Allowance of this patent application gives us 12 years of additional  protection and is a further validation of the uniqueness and innovative aspects of our lead  anticancer molecule,” he added. 

About Sunshine Biopharma’s Adva-27a 

Adva-27a is a unique anticancer compound targeted for multidrug resistant cancer. Tests  conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug  Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast  Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are  planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. 

About Sunshine Biopharma 

In addition, to working on the development of Adva-27a, Sunshine Biopharma is engaged in the  development in the development of a treatment COVID-19. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has  claimed the lives of over 2.1 million people worldwide since it first appeared in December 2019.  There are currently no drugs that can effectively arrest replication of the virus in people who have  contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent  application for several molecules which were designed by computer-aided modeling to inhibit the  Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma  has since completed the synthesis of four such molecules and identified a lead compound, SBFM-

PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is  currently advancing the development of SBFM-PL4 through the in vitro testing stage to be  followed by mice studies before entering clinical trials on COVID-19 patients. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com